E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 1/18/2008 in the Prospect News PIPE Daily.

New Issue: Accentia negotiates $8.7 million sale of convertible preferreds

By Laura Lutz

Des Moines, Jan. 18 - Accentia Biopharmaceuticals, Inc. arranged an $8.7 million private placement of convertible preferred stock with new and existing investors, according to a news release.

Rodman & Renshaw, LLC is the placement agent.

The preferreds will be convertible into common stock at $2.67 per share.

Each investor will also receive 30-day warrants for the number of shares into which that investor's preferreds are convertible and six-year warrants for half of the number of shares into which its preferreds are convertible.

The 30-day warrants will be exercisable at $2.67 for 30 days after Accentia announces unblended results of a completed phase 3 clinical trial for SinuNase. If no such announcement is made, the 30-day exercise period will begin on Dec. 2, 2008.

The six-year warrants also have a strike price of $2.67.

Proceeds will be used for drug development, regulatory strategies, marketing plans and other working capital.

Accentia is a biopharmaceutical company based in Tampa, Fla.

Issuer:Accentia Biopharmaceuticals, Inc.
Issue:Convertible preferred stock
Amount:$8.7 million
Conversion price:$2.67
Warrants:30-day for number of shares into which preferreds are convertible; six-year warrants for 50% of number of shares into which preferreds are convertible
Warrant expiration:30 days, beginning on earlier of Dec. 2, 2008 and announcement of phase 3 clinical trial unblinded results for Sinunase for two-thirds of warrants; six years for one-third of warrants
Warrant strike price:$2.67
Agent:Rodman & Renshaw, LLC
Announcement date:Jan. 18
Stock symbol:Nasdaq: ABPI
Stock price:$2.63 at close Jan. 17

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.